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potential to influence the biosynthesis of
metabolites involved in Parkinson’s disease and
schizophrenia
György AbrusánAbstract: It has been recently discovered that transposable elements show high activity in the brain of mammals,
however, the magnitude of their influence on its functioning is unclear so far. In this paper, I use flux balance
analysis to examine the influence of somatic retrotransposition on brain metabolism, and the biosynthesis of its key
metabolites, including neurotransmitters. The analysis shows that somatic transposition in the human brain can
influence the biosynthesis of more than 250 metabolites, including dopamine, serotonin and glutamate, shows
large inter-individual variability in metabolic effects, and may contribute to the development of Parkinson’s disease
and schizophrenia.
Reviewers: This article was reviewed by Dr Kenji Kojima (nominated by Dr Jerzy Jurka) and Dr Eugene Koonin.
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Transposable elements (TEs) make up at least half of
the human genome [1,2], however, the vast majority of
the approximately 3.5 million TE insertions are fixed,
ancient repeats. The overall impact of this enormous
number of insertions on the evolution of the genome is
still under intensive research; it has been shown that
at least 25% of mammalian promoters contain a trans-
posable element [3], a number of genes and protein
domains were derived from transposable elements
[1,4,5], the presence of TEs can result in alternative spli-
cing [6,7] and structural variation of the genome [8].
Other significant effects of TEs include the inactivation
of the X chromosome [9,10], or the modification of gene
expression patterns [11].
Despite the very high number of fixed insertions, the
number of transpositionally active TEs in the human
genome is surprisingly small. The only active autono-
mous transposon is the L1 retrotransposon, with ap-
proximately 80–100 copies contributing the majority ofCorrespondence: abrusan@brc.hu
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Research Centre of the Hungarian Academy of Sciences, Temesváry krt. 62,
Szeged H-6701, Hungary
© 2012 Abrusán; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orretrotransposition events in the genome [12]. In pri-
mates L1s are parasitized by Alu and SVA elements: TEs
which do not encode their own proteins, but hijack the
proteins of L1s for retrotransposition, and which (Alus
in particular) generated very high number of insertions
during the evolution of primates. Although the millions
of fixed insertions in our genome have mostly neutral,
nearly neutral or even beneficial effect on fitness, the re-
cent, polymorphic insertions of active TEs are likely to
be harmful, and were shown to be responsible for a
number of diseases, including hemophilia, leukemia,
colon cancer or breast cancer [13]. In order to reduce
their negative fitness effect on the host, TEs were
assumed to “jump” only in the germline, as somatic
insertions are not inherited, and may seriously harm the
host. This view was challenged by recent findings which
show that the rate of somatic transposition is higher
than expected [14,15]. Particularly high level of somatic
transposition was detected in the human brain [16-18],
which involves all three types of the active human retro-
transposons [16], and is ongoing in several regions of
the brain, like hippocampus, middle temporal gyrus or
caudate nucleus.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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transposition in the brain influences its functioning,
whether it is responsible for any pathological processes,
and why neural tissue is so permissive for retrotransposi-
tion. Several authors [17,19,20] proposed that, since
somatic transposition results in differences between indi-
viduals, it may significantly contribute to the cognitive
and behavioral differences between humans. On the
other hand, since TE transposition in the brain targets a
large number of genes [16] it may also contribute to
various ageing-related neurological disorders.
In this paper, I computationally investigate what effect
somatic transposition can have on the metabolism of the
brain, and the biosynthesis of its key metabolites, like
neurotransmitters. TE activity in the brain targets a large
number of genes, and can significantly influence their
functioning, either by disrupting an exon, or through in-
tronic insertions which can also greatly reduce the ex-
pression of a gene [11]. However, cellular networks in
general are quite robust against perturbations, and, as a
consequence, the reduction of expression or even knock-
down of a particular gene may not have any phenotypic
effects, either because the affected metabolites can be
synthesized through alternative pathways, or due to the
presence of isoenzymes. In consequence, it is necessary
to consider the behavior of the entire metabolic network
when analyzing the effects of individual insertions. The
analysis shows that the activity of TEs can influence the
biosynthesis of a number of neurotransmitters like dopa-
mine, serotonin or glutamate, and may contribute to
several diseases of the brain, particularly Parkinson’s dis-
ease and schizophrenia.
Estimating the effect of reduced gene expression on the
biosynthesis of metabolites
The insertion of a TE into an exon typically results in a
gene knockout, however the majority of TE insertions
identified by Baillie et al. [16] inserted into introns. In-
tronic insertions of L1 retrotransposons, especially in
the sense orientation can result in significant, ~70-fold
reduction of the expression level of the gene [11], due to
the poor transcriptional elongation of the ORF2 of L1s. I
tested whether the reduction of expression in any of the
genes of the network that was hit by a TE insertion
reported by Bailie et al. [16] has an effect on the biosyn-
thesis of any of the metabolites of the network, using a
combination of flux variability and flux balance analysis,
that has been shown to predict accurately the pheno-
typic changes associated with genetic modifications
[21,22]. No distinction between the types of inserting
TEs were made, because all of them are mobilized by
the L1 transpositional machinery, target the same inser-
tion sites, and therefore can influence the same set of
genes. Experimental studies indicate that TE insertionsaffect a very large number of cells in the brain, however
within each cell there are likely to be only a few new
insertions, therefore I assumed that only a single gene is
influenced per cell, and the synergistic effects of multiple
TE insertions were not investigated.
First, flux variability analysis was performed using the
SurreyFBA tool [23] for each of the 2766 non-boundary
metabolites of the human metabolic network, Recon1
[24], using an exchange reaction for each metabolite as
an objective function. This allowed establishing the flux
rate boundaries of each reaction when the network is
used to produce one particular metabolite. Next, I iden-
tified the genes which, at least theoretically, can be
knocked down in the metabolic network with a meta-
bolic effect – i.e. they have no isozymes. Gene expres-
sion levels and flux rates of metabolic networks can be
coupled in two basic ways: Covert et al. [25] used a bin-
ary approach to link expression with flux – above a cer-
tain expression level the flux is “on”, while below it the
reaction is essentially knocked down. In contrast Colijn
et al. [26] used continuous (e.g. linear) functions to
couple expression with flux. I used a linear function to
approximate the change in flux rates due to TE inser-
tions, because this way no additional parameters need to
be estimated. Han et al. [11] reported that L1s inserted
into an intron in a sense orientation caused a 70-fold de-
cline in the expression of the gene, and a similar, 70-fold
reduction in the flux of the reactions catalyzed by it was
assumed (note that the exact amount of flux change
assumed does not qualitatively affect our results). To de-
termine which metabolites are synthesized at a reduced
rate due to TE insertions, the change in the production
rate of each metabolite of the network was calculated,
when the reactions catalyzed by a somatic TE-insertion
containing gene had reduced fluxes (70-fold).Identification of the metabolites influenced by TE
insertions
Altogether, the TEs reported by Baillie et al. [16] inserted
into 401 genes of the metabolic network, which catalyze
780 reactions. However, in 217 cases the genes carrying
a TE insertion have isoenzymes, thus reducing their ex-
pression level, or even knocking them out by a TE has
no phenotypic effect. From the remaining 184 genes,
more than 91 have no effect individually on the biosyn-
thesis of any metabolite. Only insertions in 93 genes
resulted in a change of the biosynthesis of any metabol-
ite (Additional file 1: Table S1, Additional file 2: Figure
S1). The change in the expression of these genes influ-
enced the biosynthesis of 256 different metabolites, fre-
quently in several organelles (Additional file 1: Table S1),
including key neurotransmitters like dopamine, serotonin
and glutamate.
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three individuals (donors A, B and C), and the compari-
son of the TE-influenced metabolites show large differ-
ences between them. Altogether, there are only 9
metabolites that are influenced by TEs in all three
donors (Additional file 1: Table S1), none of which are
neurotransmitters or associated with a widespread
neurological disease. This small number of overlapping
metabolites is mostly due to Donor B, in which TEs
altogether can influence the biosynthesis of only 9 meta-
bolites, all of which are also affected in donors A and C.
The number of metabolites influenced in the other two
donors (A and C) is considerably higher (138 and 210 re-
spectively, Additional file 1: Table S1), and also the over-
lap between them is higher (69 metabolites, Additional
file 1: Table S1). The identification of metabolites which
are consistently influenced by TE activity in most
humans would require data from much more donors,
nevertheless the large variability seen in these three indi-
viduals already highlights the very large differences in the
effect TEs can have in different individuals.
Metabolic fingerprints of diseases influenced by TE
insertions
The reduced biosynthesis of neurotransmitters and other
metabolites can result in several diseases of the central
nervous system (CNS), and also diseases can manifest
themselves with characteristic metabolic profiles. I tested
whether the metabolites that are influenced by the activ-
ity of TEs are associated with diseases of the CNS, using
the metabolite – disease associations provided by the
Human Metabolome Database (v.2.5) [27]. The pooled
data from all three donors show that TE insertionsTable 1 The list of diseases of the central nervous system (CN
insertions
Nr. Disease Expected SD Observed P
1 Parkinson’s
disease
2.318 1.734 7 0.004 3-Methoxytyra
2 Alzheimer’s
disease
6.539 1.433 8 0.244 3,4-Dihydroxy-
Succinate,L-Ty
3 Schizophrenia 2.447 1.257 5 0.040 4-Hydroxyphe
4 Canavan disease 2.967 1.104 4 0.338 Oxidized gluta
5 Autism 0.156 0.377 2 0.005 L-Cystathionin
6 Epilepsy 3.156 1.184 4 0.376 4-Hydroxyphe
7 Friedreich’s
ataxia
0.222 0.443 1 0.210 Homovanillate
8 Major depressive
disorder
0.636 0.589 2 0.057 Homovanillate
9 Multiple sclerosis 3.458 1.489 5 0.224 Cholesterol,Fe
10 Hypothyroidism 3.100 1.484 6 0.027 Dopamine,Ho
The expected numbers of such metabolites (+/− SD), and P were estimated by Mon
expected if the same number of TE insertions as observed by Baillie et al. (16) were
Hypothyroidism is also included, because it shares metabolites with several diseasereduce the biosynthesis of several metabolites that are
linked to a disease, most importantly metabolites con-
nected with Parkinson’s disease, Alzheimer’s disease, or
schizophrenia (Table 1). However, this is partly due to a
simple mass-effect: inserting a sufficiently large number
of TEs into random genes is likely to result in changes
in the biosynthesis of several metabolites, some of which
can be expected to be linked to diseases of the CNS. To
separate the diseases which may simply be byproducts of
random effects (i.e. mostly the magnitude of TE activity)
from those that are the results of the target-specificity of
transposition, Monte Carlo simulations were performed
to determine the expected number of affected metabo-
lites given the number of observed TE insertions. The
endonuclease of L1 retrotransposons has a relatively well
defined target site preference, and typically nicks DNA
at TT|AAAA hexamer [28] and its variants. I first identi-
fied the location of possible target sites (TTAAAA hex-
amers on both strands, allowing for one mismatch) in all
1496 genes of the human metabolic network. Next, the
TE insertions were randomly distributed across these
target sites 100 000 times, generating random samples.
In each random sample, the genes containing the TE
insertions, and those metabolites which are synthesized
at a reduced rate due to these insertions were deter-
mined. Using the Human Metabolome Database [27], I
identified the number of metabolites in each sample that
are connected to a particular disease, and tested whether
the number of such metabolites observed in samples
from the brain is significantly higher than the random
expectation using the equation: p = ( n + 1 ) / ( N + 1 ),
where p is statistical significance, n is the number of










2+,Oxidized glutathione, Reduced glutathione,24-Hydroxycholesterol
movanillate,Serotonin, L-Thyroxine,Triiodothyronine,L-Tyrosine
te Carlo simulations, which show how many such metabolites would be
distributed across the genes of the human metabolic network randomly.
s of the CNS, like dopamine, serotonin, homovanillate or L-Tyrosine.
Figure 1 The pathways of tyrosine metabolism which are most influenced by somatic transposition in the brain. Reactions with their EC
numbers or catalyzing gene are represented with diamonds, metabolites with squares. Reactions which are influenced by TE insertions are
highlighted with red; metabolites, which in consequence can be produced only at reduced rate are highlighted with blue. These include key
metabolites like tyrosine, dopamine, glutamate, homovanillate or melanin.
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random samples (100 000).
The results show that the number of metabolites influ-
enced by TEs is significantly higher than expected by
chance in the case of Parkinson’s disease and schizo-
phrenia, and also autism, although in the latter only very
few metabolites are involved (Table 1). A large fraction
of TE-influenced metabolites that could be linked to a
disease of the CNS is synthesized in the tyrosine meta-
bolic pathway, like dopamine, homovanillate, 3-metoxy-
tyramine, tyrosine or 4-hydroxyphenylacetate (Figure 1),
but also other key metabolites like glutamate or melanin.
Individual donors however, although show an enrich-
ment of disease linked metabolites for most diseases of
the CNS (Additional file 1: Table S2), do not show sig-
nificant effects, which is consistent with the donors
being healthy individuals.
Possible contribution of TE activity to the development of
neurological disorders
The results indicate that TE activity in the brain can in-
fluence the biosynthesis of several metabolites, including
key neurotransmitters like dopamine, serotonin and glu-
tamate, and that Parkinson’s disease (PD) in particular,
but also schizophrenia (SZ) and autism are the prime
candidates for diseases where the somatic activity of TEs
can contribute to the causes. TEs may contribute to
these diseases in different ways. First, continuous trans-
position into genes responsible for, for example tyrosine
metabolism can gradually reduce the brain’s ability to
synthesize dopamine and related metabolites (Figure 1,
Table 1), which may result both in its lowered overall
levels, and regional differences within the brain. As TEs
are known to be mobilized by environmental stressors
[29-31], the magnitude of this process may be signifi-
cantly influenced by the environment of individuals,
which is consistent with the observed large differences
between the three donors. Second, transposition may
simply result in the loss of neurons, and thus regional
differences in TE activity can also result in the faster de-
terioration of the tissues more prone for transposition.
Our current knowledge on these diseases supports
these hypotheses. In the case of PD the underlying cause
is unknown, its heritability is low [32,33], the susceptibil-
ity loci identified by genome-wide association studies
[34] explain only a fraction of the cases, and its onset is
thought to be mostly due to environmental factors [35].
The main symptoms of PD are caused by the reduction
of dopamine production in the brain, particularly by the
gradual decay of dopaminerg cells in the substantia nigra
[35]. The case of SZ is probably more complex, as sev-
eral disorders (psychoses, manias, SZ) form a continuum
of symptoms, and may have different physiological
causes. Unlike in PD the heritability of SZ is high[36,37], however it is inherited in a non-Mendelian man-
ner and it has proved to be remarkably difficult to iden-
tify the susceptibility loci [37,38]; the current view is
that thousands of loci may contribute to the disease
[37]. However, dopamine (and in consequence tyrosine
metabolism) is also thought to have a critical role in the
development of symptoms, although in a more complex
way than in the case of PD, as the amount and sensitiv-
ity for dopamine in SZ patients shows regional differ-
ences in the brain: deficiency in the prefrontal cortex
and hypersensitivity of dopamine receptors in the meso-
limbic pathways; it is likely that the dysregulation of
dopamine levels is the primary cause of the disease [39].
Although major depressive disorder (MDD) shows
only borderline significance (p = 0.057), the possible in-
fluence of TEs on serotonin levels suggests that TEs
might be involved to a certain degree. The heritability of
MDD is intermediately high, 37% [40]; its causes are
largely environmental, stress related, and most likely
linked to the loss of neurons in the limbic structures of
the brain, e.g. hippocampus [41].
Since the frequency of these diseases in the population
is relatively low (1-2% for PD and SZ, 10% for MDD),
and all three donors were individuals with no signs of
neurodegenerative diseases [16], one should not expect
the signatures of full-blown diseases in this dataset, ra-
ther indications pointing towards such conditions. I
hypothesize that, similarly to diseases like cancer, where
the causative mutations can accumulate for decades be-
fore the malignant transformation, a long term accumu-
lation of TE insertions in the brain is necessary for the
emergence of these diseases, and that their effects reach
the necessary threshold only in a fraction of individuals.
Overall, the analysis shows that the ability of TEs to
interfere with the biosynthesis of several metabolites,
particularly tyrosine metabolism may contribute to sig-
nificant neurological disorders, and – unless it provides
some key benefits for the CNS – to reduce their inci-
dence it may be necessary to develop drugs that halt
somatic transposition in the brain.
Additional files
Additional file 1: Table S1, Table S2.
Additional file 2: Figure S1. The matrix of genes and metabolites
that are influenced by TE insertions. It was assumed that the insertion
of a TE results in a 70-fold reduction of the expression and flux of the
reactions catalyzed by the gene, which, however, due to compensatory
effects in the network may result in a much smaller reduction in the rate
of the biosynthesis of the influenced metabolites.
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Reviewer 1: Dr Kenji Kojima, Genetic Information Research Institute,
Mountain View, CA, United States of America (nominated by Dr Jerzy
Jurka, Genetic Information Research Institute, Mountain View, CA,
United States of America)
The manuscript by Abrusán et al. describes computational analysis of the
effects of transposon insertions reported by Baillie et al. 2011. The main
point of this manuscript is to demonstrate the potential contribution of
transposon insertions to neurological disorders by an analysis taking
metabolic networks into account. While the topic is very interesting, and the
approach is innovative, there are problems with the analysis, so I
recommend that the authors reanalyze the data.
Major points:
The most significant problem is the reliability of the analysis reported at
pages 7–8. Target specificity of L1 for TT/AAAA is not high, and most of L1
(and Alu and SVA) are inserted into variants of TT/AAAA. However, in their
Monte Carlo simulations, the authors assume that L1/Alu/SVA elements are
exclusively inserted into TT/AAAA. Therefore, the expected numbers in these
simulations may be unrealistic. There may be significant differences between
the real data from the simulations due to non-specific insertions. Potentially,
some of the genes causing these diseases may have more sites similar to
TTAAAA than expected by chance.
Authors’ response: I relaxed the required target specificity in the randomization
protocol, and allowed for one mismatch at any position along the TTAAAA
hexamer. This resulted in somewhat less significant enrichments (most notably
in the case of major depressive disorder, where p = 0.057, and also for Donor A,
Additional file 1 Table S2), but did not change the main conclusions of the
manuscript.
The authors assume that insertions of Alu and SVA reduce transcription of
inserted genes in the same way as L1. However the 70-fold reduction in
transcription of gene inserted by L1 is likely to be L1-specific and not
applicable to Alu and SVA insertions.
Authors’ response: Certainly, Alu insertions ale less deleterious than L1s, and it is
also less easy to quantify their direct effects caused for example by alternative
splicing. I treated all TE insertions similarly, because all of them are mobilized by
the L1 transpositional machinery, target the same sites, and I was primarily
interested in the genes the can be targeted by L1s. (Basically I assumed that
individual insertion sites/insertions are not similar between individuals, but that
transposition is constrained to a limited number of genes). Also, I was mostly
interested in the qualitative effects on metabolism (i.e. which metabolites are
influenced), rather that the quantitative effects (how much flux is reduced), and
the conclusions would be equally valid if I would have assumed a 50% (or
other) reduction in flux after a TE insertion.
The information in the materials and methods is not detailed enough for a
full evaluation. Due to a limited description, it is not clear whether the
authors take downstream cascade of the network into account. For example,
if the expression of Tyramine is reduced by the transposon insertion the
downstream metabolites such as 4-Hydroxyphenylacetaldehyde and 4-
Hydroxyphenylacetate should be also reduced.
Authors’ response: In estimating the impact of a gene, our flux balance analysis-
based approach takes into account every metabolite influenced by the change
of expression of that particular gene within the network, including changes
resulting from a downstream cascade.
Quality of written English: Acceptable
Reviewer 2: Dr Eugene Koonin, NCBI, NLM, NIH, United States of America
This is a very straightforward analysis with extremely interesting, provocative
results. Somatic transposition is a remarkable, novel phenomenon, and here
it is convincingly shown with flux balance analysis that such transpositions
could reduce expression of many enzymes and consequently affectbiosynthesis of neurotransmitters (among other metabolites). Still, the
connection to diseases is fully circumstantial, so although the authors do not
hide this, perhaps even more caution is advisable. In particular, I would feel
more comfortable with a title like:
“Somatic transposition in the brain has the potential to influence the
biosynthesis of metabolites involved in Parkinson’s disease, schizophrenia
and depression”
Authors’ response: I changed the title as suggested.
Quality of written English: Acceptable
Reviewers’ comments (after revision)
Reviewer 1: Dr Kenji Kojima, Genetic Information Research Institute,
Mountain View, CA, United States of America (nominated by Dr Jerzy
Jurka, Genetic Information Research Institute, Mountain View, CA, United
States of America)
My concern is the simulation study in order to distinguish random effects
from target-specific transposition. The meaning of “target specificity of
transposition” in the text is unclear, but I speculate that it does not mean
the L1’s target sequence preference but a tendency to be inserted into
genes related to diseases. However the author’s simulation is not suitable to
distinguish these two effects. The author allowed one mismatch in target
TTAAAA hexamer in the null hypothesis, but still it could be distant from the
actual integration pattern of L1 (and Alu, SVA). In that case, although
tendency of L1 to be inserted into genes related to diseases is not rejected,
the statistical significance may suggest different sequence preference of
target site selection by L1. Even if the claim is true, the author should
propose an explanation for why transposons are accumulated in genes of
certain metabolic pathways related to diseases.
Authors’ response: By target specificity I mean insertion site specificity, i.e. the
preferential insertion into the TTAAAA hexamer and its variants. No other
adjustments were made in the randomization, thus any differences from the
random expectation are likely to be caused by a biological process, for example
by preferential insertion of TEs into genes that are overexpressed in the brain
(which was already noted in the study of Baillie et al. 2011).
Quality of written English: Acceptable
Reviewer 2: Dr Eugene Koonin, NCBI, NLM, NIH, United States of America
I have no further comments regarding the content of the manuscript, my
review and the author’s response.
Quality of written English: Acceptable
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